MYGN

Hart Jayne B.

Known title: Chief People OfficerCIK: 0001519749

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 27, 2026

Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis. An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.

this person other insiders at MYGN

Transaction History

MYGN▼ Sell$39K
MYGN▼ Sell$58K
MYGN▼ Sell$41K
MYGN▼ Sell$31K
MYGN▼ Sell$29K
MYGN▲ Buy$15K
MYGN▼ Sell$37K
MYGN▼ Sell$55K
MYGN▲ Buy$0
MYGN▲ Buy$168K
MYGN▼ Sell$175K
MYGN▲ Buy$84K
MYGN▼ Sell$88K
MYGN▲ Buy$0
MYGN▲ Buy$3K
MYGN▼ Sell$61K
MYGN▼ Sell$91K
MYGN▼ Sell$74K
MYGN▼ Sell$129K
MYGN▲ Buy$0
MYGN▲ Buy$1.9M
MYGN▼ Sell$2.2M
MYGN▲ Buy$100K
MYGN▼ Sell$100K

We use analytics to understand how market-wall is used. No personal data is sold.